ARCHIVES

ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

Consensus Panel Say Surgery, Radiation Both Effective For Clinically Local Prostate Cancer

June 26, 1987

Guest Editorial: Omics Checklist Done, Now Create Business Model For Tests

February 7, 2013

NCI relaxes Core Grants Support For Clinical Trials Research

December 11, 1992

Rogers Eyes Saccharin Ban

March 18, 1977

DCT Advisors Approve Five Trials For High Priority Status

April 7, 1995

ODAC Nixes Sanofi’s VTE Drug in 14-1 Vote, Setting High Bar For Adjunctive Therapies

June 22, 2012